Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional Accepts healthy volunteers

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

ClinicalTrials.gov ID: NCT06480201

Public ClinicalTrials.gov record NCT06480201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 27, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relative importance of GBP to antidepressant symptom reduction across the induction phase of treatment. If successful, it provides a compelling rationale for a larger prospective investigation of gamma dynamics as a moderator of outcome to varied TRD therapies which impact the balance of cortical excitation and inhibition.

Study identification

NCT ID
NCT06480201
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Texas A&M University
Other
Enrollment
100 participants

Conditions and interventions

Eligibility (public fields only)

Age range
21 Years to 45 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2023
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026
Last update posted
Jul 5, 2026

2024 – 2026

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Wells Medicine Houston Texas 77024 Recruiting
Texas A&M (Houston Methodist Hospital Location) Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Healthy trials

Other public records listing Healthy. Sorted by last update posted; newest first. Not a recommendation.

All Healthy trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06480201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 5, 2026 · Synced Jul 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06480201 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →